# Genflow Biosciences in focus as longevity research expands into animal health

- Link: https://www.directorstalkinterviews.com/genflow-biosciences-in-focus-as-longevity-research-expands-into-animal-health/4121268219
- Published: 2026-10-28T13:00:00+00:00
- Author: Amilia Stone

Genflow Biosciences highlights the growing commercial interest in longevity science
as research into extending healthy lifespan expands beyond human medicine to include
companion animals.

The growing interest in animal longevity could create opportunities for biotechnology
companies working on the biological mechanisms of ageing. Genflow Biosciences is
focused on longevity science, including research into the SIRT6 gene and its potential
role in healthy ageing. However, the animal longevity developments discussed here
should not be interpreted as evidence that Genflow has a canine treatment or programme.

The emerging animal longevity sector is attracting researchers and businesses interested
in whether scientific advances could help pets live longer, healthier lives. Dogs
are a particular focus because their ageing process can be studied over a shorter
period than human ageing, potentially allowing researchers to assess interventions
and their effects on age-related changes.

For Genflow, the wider interest in longevity research provides context for its work
on ageing biology. The company’s approach centres on SIRT6, a gene associated with
DNA repair, genome stability and metabolic regulation. Research into these processes
is part of a broader effort to understand why organisms age and whether biological
mechanisms linked to ageing can be targeted therapeutically.

The commercial potential of longevity science depends on translating early research
into safe and effective treatments. Animal longevity research may offer opportunities
for veterinary medicine, but it remains a distinct field with its own regulatory
requirements, clinical evidence and commercial considerations. Results from animal
studies cannot automatically be applied to humans, nor can findings from human-focused
research be assumed to translate into treatments for dogs.

_**[Genflow Biosciences plc](https://www.directorstalkinterviews.com/company/genflow-biosciences-plc/genf.l)**(
LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in
Belgium focused on developing novel therapeutic approaches that potentially halt
or slow the aging process in humans and dogs supporting longer, healthier lives_

Share on:
